Abnova offer a series of new monoclonal research antibodies to support the study of the Zika virus. These are available through tebu-bio across Europe. Let’s take a look at these monoclonals, 100% validated for immuno-assay applications.
Abnova offer a series of new monoclonal research antibodies to support the study of the Zika virus. These are available through tebu-bio across Europe. Let’s take a look at these monoclonals, 100% validated for immuno-assay applications.
Protein Gene Product 9.5 (PGP 9.5) is an abundant cytoplasmic neuron and neuroendocrine-cell specific protein. Over the years, this deubiquitinating enzyme (a.k.a. Ubiquitin Carboxy-terminal Hydrolase L1 (UCH-L1)) has become an accepted biomarker for neurons and cells of the diffuse neuroendocrine system (DNES) but also when studying neurodegenerative disorders (e.g. Alzheimer’s and Parkinson’s diseases) and cancers.
Research antibodies specific for PGP9.5 / UCH-L1 stain neuronal cell bodies and axons in the central and peripheral nervous systems, small nerve fibres in nerve tissue, neuroendocrine cells in the pituitary, thyroid pancreas, and also tumours of the DNES.
In this context, Cedarlane just release 2 new anti-PGP9.5 / UCHL1 rabbit polyclonal antibodies fully validated & guaranteed for IHC analysis of Paraffin Embedded Sections, IF and WB applications on Human, Rat and Mouse tissues.
Determining the linkage of polyubiquitin on target proteins is challenging. The traditional methods are either through Mass Spectrometry or immunoblot with linkage specific antibodies, which are cumbersome. LifeSensors has developed the UbiTest assay, a more definitive method for demonstrating the ubiquitylation linkage of a protein, which is to couple immunoprecipitation of polyubiquitylated protein with digestion by a linkage specific deubiquitylase prior to immunoblot analysis. An increased signal for the unmodified substrate or a decreased signal of polyubiquitylated substrate at high molecular weight after K48/K63 specific DUB treatment is a clear indication that the protein was K48/K63 ubiquitylated.
As a member of this network, tebu-bio will again be participating in this trade show focussed on open innovations. This congress is an excellent opportunity to discover the innovative solutions designed by tebu-bio laboratories in the field of R&D and in vitro testings aiming at better understanding the mechanisms of action and further assessing the efficiency of ingredients.